Stay on top of the latest research and practice
The ESGO 2017 Keynote Lectures will be delivered by Josef Penninger and Christian Marth, and will be dedicated to special topics in Ovarian Cancer.
Christian Marth, Austria
Josef Penninger, Austria
Keynote Lecture Topic:
Christian Marth, MD, PhD, is the Director of the Department of Obstetrics & Gynecology at the Innsbruck Medical University, Austria.
Currently he holds leadership roles as the Chair of ENGOT, President of the Austrian Association for Gynecologic Oncology (AGO) and Vice President of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Christian Marth has been the author or co-author of more than 370 scientific articles.
Josef Penninger, MD was formerly a lead researcher at the Amgen Research Institute in Toronto. In 2002 he accepted the appointment as founding director of the newly established Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna, Austria.
Major achievements include pioneering insights into the molecular basis of osteoporosis and breast cancer, as well as the study of metastatic spread. His group has also developed the first haploid embryonic stem cells for functional genetics. He has authored and co-authored more than 580 scientific papers.
Josef Penninger’s major awards include the Descartes Prize, the Wittgenstein Prize of the Austrian Federal Government, the Ernst Jung Prize for medical excellence, an AAAS Award the Innovator Award from Era of Hope/DOD and a second ERC Advanced grant.
David Cibula, Czech Republic
Michael Seckl, UK
Isabelle Ray-Coquard, France
Sandro Pignata, Italy
David Cibula is the organizer of postgraduate meetings, including the International Videoworkshop on surgery in gynecological oncology, founder and President of the Czech Society of Hospital Gynecologists and Obstetricians, founder and President of the Central and Eastern European Gynecologic Oncology Group (CEEGOG), author of over 300 publications, H-index 2, and currently the President of the European Society of Gyneological Oncology (ESGO).
Michael Seckl trained in medicine at University College London/UCLH undertaking an intercalated BSc in Immunology and qualifying in 1986. After obtaining his MRCP he specialised in medical oncology doing a PhD in cell signalling at the London Research Institute (then ICRF) prior to his appointment as a Senior Lecturer/ honorary consultant in 1995 at Charing Cross Hospital/Imperial College London. Here he works clinically on gestational trophoblastic disease (GTD), germ cell tumours and lung cancer.
His laboratory science is focused on elucidating mechanisms of resistance to therapy and cancer metastasis to facilitate novel biomarker and therapy development. He was made a Reader in 2000 and a Professor of Molecular Oncology in 2002. In 2004 he became the director the UK and world’s largest GTD centre and is an international leader in this area. He is a former president and current treasurer of the International Society for the Study of Trophoblastic Disease (ISSTD), a gold medal holder of the ISSTD and president-elect of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD). He is also director of the new malignant ovarian germ cell tumour service, director of postgraduate studies for the Dept of Surgery and Cancer and the Imperial College Experimental Cancer Medicine Centre.
He is an editor of several journals, sits on numerous national and international committees and has published more than 190 papers. Many have appeared in prominent journals such as NEJM, Lancet, Lancet Oncol, J Clin Oncol, Cancer Res, EMBO J, EMBO-R, Sci Transl Med and Oncogene. His work is currently supported by grants from CR-UK, MRC, AICR, EU FP7, industry, Dept of Health and other charitable sources.
Isabelle Ray-Coquard, MD, PhD, is medical oncologist in the Medical Oncology Department and the Institute for Clinical Science at the Centre Leon Berard, the regional Cancer Center in Lyon, France. She is also Professor of Medical Oncology in University Claude Bernard Lyon I, France.
Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the factors that determine medical practices in oncology. Prof. Ray-Coquard also received Master’s degrees in medical economy in 1996 and in statistics in 1995.
Since 2005, Prof. Ray-Coquard has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national observatory dedicated to rare ovarian cancer, a network funded by the INCA commission and dedicated to the management of all rare ovarian cancer.
At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), Prof. Ray-Coquard has been active in the translational research advisory committee, the scientific committee, the rare tumors committee, and as a chairman of endometrial cancer subgroup. She is the current Past-President of GINECO. Since 2009, Prof Ray-Coquard is the chairman of the rare cancer working group from GCIG (gynaecological cancer intergroup) dedicated to clinical trials in the field of all gynaecological cancers.
Prof. Ray-Coquard is an active member of a number of professional groups, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation and the European Society of Medical Oncology. Prof. Ray-Coquard has co-authored more than 230 peer-reviewed articles and over 200 abstracts and book chapters with an H factor of 34.
Sandro Pignata studied medicine at the University “Federico II,” Naples, Italy, where he graduated in 1986. He went on to specialize in Gastroenterology in 1990 and then in Medical Oncology in 1998. In 1996 he obtained his PhD in Gastrointestinal Physiology at the University “La Sapienza” in Rome. Since 1993, Dr Pignata has been a member of staff at the National Cancer Institute in Naples, where he is now the head of the Uro-Gynaecological Department. Dr Pignata is also president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, that is the largest research group in the field of gynaecologic oncology in Italy and one of the largest in Europe, with more than 80 Italian centres involved in several randomised trials on the treatment of gynaecological cancer, whose results have been published in leading international journals. Through his work with the MITO group, Dr Pignata promoted translational research, creating in 2011 an independent network including 11 laboratories throughout Italy. The clinical researchers have successfully collaborated with such translational network, especially in the collection of cancer specimens for biobanking aiming to identify both predictive biomarkers of response to treatment and prognostic factors in patients suffering from gynaecological malignancies. Dr Pignata participated in the preparation of the national guidelines on the treatment of ovarian, uterine, cervical and renal carcinoma. He is the first author of several papers that have contributed to changing the paradigm of gynaecological cancer treatment. As Principal Investigator and head of the coordinating centre of several multicentre phase I-IV trials, Dr Pignata is contributing to the development of new tailored therapies in ovarian cancer. His work has recently been focused on the understanding the role of angiogenesis pathway’s inhibition in the first (MITO-16A-MANGO OV2A phase IV trial) and second line in both platinum sensitive (MITO-16b – MANGO-OV2b – ENGOT-ov 17 phase III trial) and resistant ovarian cancer treatment (MITO 11 phase II trial). Dr Pignata is member of the ESMO Faculty Group in Gynaecological Cancers and member of the board of Directors of the Gynecologic Cancer InterGroup (GCIG) as well as member of the Council of the European Society of Gynecological Oncology (ESGO). He is in the editorial boards of international journals such as Annals of Oncology. Dr Pignata is currently the president elect of the European Network of Gynaecological Oncological Trial Groups (ENGOT) that coordinates, promotes clinical trials within 20 trial groups from 15 European countries and performs cooperative clinical trials on patients with gynaecological cancer. He is a member of the Italian Association of Medical Oncologists (AIOM) and of the Gynaecological Group of the European Organization for the Research and Treatment of Cancer (EORTC).
Jonathan Ledermann, UK
Anna Fagotti, Italy
Vesna Kesic, Serbia
Frédéric Amant, Belgium
Jonathan Ledermann trained in medical oncology in London and Toronto and specialises in the treatment of gynaecological cancers and clinical trials. His clinical practice is at the Gynaecological Cancer Centre at UCL Hospitals in London. Over the last 15 years he has led several national and international trials in ovarian cancer. He is Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the national cancer trials units in the UK. He is the past chair of the NCRI Gynaecological Cancer Studies Group and co-chair of the Rare Tumor group in GCIG. He is a member of ESGO Council and Chair of the non-surgical subgroup of the British Gynaecological Cancer Society. He is a Senior Associate Editor of International Journal of Gynecological Oncology and on the Editorial Board three other journals . His principal areas of research, publication and education are in clinical trials in gynaecological cancers and experimental therapeutics.
Assistant Professor at the University of Perugia, Italy. PhD in “Molecular Pathology in Gynaecological Oncology”. Member of the Executive Board of the Italian Society of Gynaecological Oncology (SIOG) affiliated with the ESGO. Advisor of the Italian Society of Gynaecological Endoscopy (SEGI) affiliated with the ESGE. Author of more than 100 peer reviewed papers. Faculty of national and international standardized training programmes for advanced laparoscopic and LESS gynaecological surgery at the Catholic University of the Sacred Heart, Rome, Italy.
Dr Vesna Kesic finished medical and postgraduate medical studies at the Medical Faculty, University of Belgrade. From 1986-1990, she was specializing in Obstetrics and Gynecology. In 1990 she got a PhD in Gynecologic Oncology, and in 1996 she finished sub-specialization in Oncology, at the same University. Dr Kesic has started her University career in 1992 and in 2005 became the Associate Professor of Gynecology and Obstetrics at the Medical School, University of Belgrade. She achieved full professorship in 2012.
Dr Kesic is one of the leading specialists in gynecological oncology in her country. She has been trained in Obstetrics and Gynecology in UK, USA and Norway. In 2002 she has been nominated the Serbian Ministry of Health Adviser for prevention and early detection of cervical cancer. From 2008 she is the president of the National Advisory Board for cervical cancer prevention. In 2008 she became a member of Serbian Academy of Medical Sciences and Serbian Scientific Society.
Dr Kesic has published 124 articles in international and national journals, was the author of 4 books and 20 chapters in international and national books and was invited lecturer for more than 130 presentations. Apart from her fruitful work in developing gynecological oncology in her own country, she is particularly active in education, organizing or coordinating colposcopy and gynecological oncology courses and training in Eastern Europe, Middle East, Africa and Asia. From 2006 to 2010, as a Council member of International Society for Gynecologic Cancer (IGCS), dr Kesic developed the program of workshops and supported meetings and helped organization of 28 events attended by more than 4000 participants. She was running similar activity in European Society for Gynecologic Cancer (ESGO) and from 2005 by now, 58 Workshops and endorsed meetings were organized under the patronage of ESGO in Central and Eastern European countries. She was the president of the 4 th European congress of colposcopy (2007) and 16 th ESGO congress (2009), both organized in Belgrade. Dr Kesic was the principal researcher in the three successfully finished international and participated several national projects. She was also the scientific leader of the pilot project for screening of cervical cancer in Branicevo region, the first organized screening program in Serbia.
Now, she is conducting a Ministry of Health project: “Organization of Referral center for cervical cancer” and Ministry of Science project “Cancer and Pregnancy”. Her professional affiliations include membership in the Serbian Medical Society, International Society for Gynecologic Cancer, European Society for Gynecologic Oncology, European Association of Cancer Research and American and British Societies for Colposcopy and Cervical Pathology. She is the founder and past-president of Serbian Society for Gynecologic Oncology. Dr Kesic was the Secretary General of the Yugoslav Society of Colposcopy and Cervical Pathology (1995-2003).
Currently, she is the President of Serbian Society for Colposcopy and Cervical Pathology. From 2006 to 2010, dr Kesic was a Council member of the International Gynecological Cancer Society. In European Society for Gynecologic Oncology (ESGO), she has been a Council member since 2005 and Chair of the Educational Committee. In 2011, she became president-Elect of ESGO. International federation of Gynecology and Obstetrics (FIGO) has selected dr Kesic to receive a FIGO Award in Recognition of Women Obstetricians/Gynaecologists at the XX FIGO World Congress in 2012.
Frédéric Amant, MD, PhD (°1967), received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998, and his subspecialty training in gynecologic oncology in 2000. He is professor at the KU Leuven, Belgium. He is a specialist in Gynecologic Oncology at the University Hospitals Leuven (UZ Gasthuisberg), Belgium and at Antoni van Leeuwenhoek – Netherlands Cancer Institute (Center for Gynecologic Oncology Amsterdam). At KU Leuven he heads the scientific section of this specialty.
Frédéric Amant heads the International Network on ‘Cancer, Infertility and Pregnancy’ (INCIP) of the European Society of Gynecologic Oncology (ESGO). He chairs the Endometrium Tumor Site Committee of the European Organization for Research and Treatment of Cancer (EORTC), Gynecologic Cancer Group. He chairs the European Network Individualized Treatment Endometrial Cancer (ENITEC), a task force within the ESGO. He chairs the patient derived tumour xenograft platform (Trace) at the KU Leuven and is member of the European consortium on xenografts (EuroPDX).
Alexandra Taylor, UK
Carien Creutzberg, NL
Glenn McCluggage, Ireland
Xavier Matias-Guiu, Spain
Dr Alexandra Taylor is a Consultant in Clinical Oncology specialising in the treatment of gynaecological cancer at The Royal Marsden Hospital, London, UK. She is Chair of the London Cancer Alliance Gynaecology Oncology Pathway Group and a member of the UK National Clinical Studies Group for Gynaecological Cancer. She undertook her medical training at Emmanuel College, University of Cambridge, and then Guy’s Hospital, University of London, where she was awarded the Treasurer’s Medal for Medicine. She completed an MD thesis at St Bartholomew’s Hospital and the University of London. Her research focused on target volume definition including lymph node mapping and the development of novel radiotherapy techniques for cervical cancer. Dr Taylor has a particular interest in advanced radiotherapy technologies, including IMRT, image-guided brachytherapy and CyberKnife treatments. She is actively involved in research, with ongoing projects exploring novel radiotherapy techniques for recurrent gynaecological cancer, IMRT applications and integration of functional imaging with radiotherapy planning.
Carien Creutzberg is Professor of Radiation Oncology at the Department of Radiaton Oncology at Leiden University Medical Center, the Netherlands. She has completed clinical training in Radiation Oncology at Erasmus MC Cancer Center in Rotterdam in 1993, and has defended her PhD thesis at the Erasmus University Rotterdam in 1998. She moved to Leiden University Medical Center in 2000, and continued to combine patient care with clinical research and teaching of students and residents.
Her scientific and educational activities are consistent with her specialisation in Gynecologic Oncology. She has been initiator and principal investigator of the PORTEC-1 (1990-97), PORTEC-2 (2002-06), PORTEC-3 (2006-2013) and PORTEC-4 trials, and has been awarded Dutch Cancer Society Grants for all of the PORTEC trials, and for translational research and rehabilitation projects. She has been initiator of the PORTEC Study Group (1990), and was one of the initiators of the Dutch Gynecologic Oncology Group (2009), of which she is board member.
She is Council member of the European Society of Gynaecological Oncology (since 2013), and ESMO Faculty member for Gynaecological cancer. She has been member of the Uterine Corpus Cancer Task Force of the National Cancer Institute USA (2007-2013), and Council member of the International Gynecologic Cancer Society (2008-2012). She is supervising PhD theses on adjuvant treatment and late effects, rehabilitation after treatment, and translational research based on the PORTEC-trials and related studies. She has been an invited speaker at numerous national and international scientific meetings on Gynecologic Oncology and Radiation Oncology, and has written many articles, book chapters and commentaries. Her research in radiation therapy for endometrial cancer has had profound impact on treatment guidelines and research programs for Endometrial Cancer worldwide.
Prof. W Glenn McCluggage is a consultant Histopathologist in Royal Group of Hospitals Trust, Belfast and an Honorary Professor in Gynaecological Pathology of Queen’s University of Belfast. He has published approximately 400 papers in peer reviewed journals, including original publications and many invited editorials and reviews. He is on the Editorial Board of four major pathology journals and associate editor of Histopathology. Currently, the President of International Society of Gynecological Pathologists and was previously the President of the British Association of Gynaecological Pathologists. He has an extremely busy referral practice and has been invited to lecture at numerous national and international meetings. He has authored or co-authored the various Royal College of Pathologists datasets in United Kingdom on reporting of gynaecological malignancies and has chaired the ICCR (International Collaboration in Cancer Reporting) panels developing international guidelines for reporting endometrial and ovarian carcinomas. He has been part of the last 2 WHO groups formulating the classification of Tumours of the Female Genital Tract. His main diagnostic interests are gynaecological malignancies and the uses of immunohistochemistry in gynaecological pathology.
Xavier Matias-Guiu has been always interested in understanding the morphologic appearance of the tumors at the microscope on the basis of the genetic and epigenetic changes. He obtained his PhD in 1987 in Barcelona. In 1991-92, XM was Research Fellow in Pathology at the New England Medical Centre/Tufts University under the supervision of Professors H Wolfe and R DeLellis. During his stay in Boston, he learnt molecular pathology techniques, and how to apply them to understand the morphological features of the tumors. From 1986 to 2002, we worked with Professor Jaime Prat in Hospital Sant Pau, Barcelona. Currently, he combines the scientific direction of IRB LLEIDA with supervision of the routine pathology work as Chairman of Pathology at Hospital Universitari Arnau de Vilanova, and the direction of a research group as Professor of Pathology at University of Lleida, devoted to understanding the molecular basis of some tumors, preferentially endometrial carcinoma. XM has participated in the panel for defining the WHO classification of the tumors of the Female Genital Tract (Pathology and Genetics), specifically endometrial carcinoma. Results obtained during the last 15 years have allowed XM to understand the molecular features of endometrial carcinoma (microsatellite instability, as well as mutations in PTEN, PI3KCA, CTNNB1, k-RAS, inactivation of SPRY2 and RASSF1A), expression profile of type I and type II, molecular features of myometrial invasion and metastasis, and resistance to apoptosis/hypoxia/radiation). The group is multidisciplinary, composed by clinician, pathologists and basic researchers, and assesses molecular features of endometrial carcinoma in an integrated approach, from tumor tissue to patient care, using different materials (tumor tissue, cell lines, tumor explants, mice models, three-dimensional cultures) and methods (tissue arrays/immunohistochemistry), molecular biology (mutation analysis, sequencing, MLPA, microsatellite PCR, methylation specific PCR, FISH, RT-PCR, expression arrays, proteomics, metabolomics) and cell biology (viability, proliferation, apoptosis, clonogenic assays in cell lines and tumor explants; gene overexpression, interference RNA).
Sigurd Lax, Austria
Ignace Vergote, Belgium
Philippe Morice, France
Dominik Denschlag, Germany
Dr. Sigurd Lax is Professor of Pathology and since 2002 head of the Department of Pathology of the academic teaching hospital Graz Süd-West. He graduaded from the University of Graz, School of Medicine in 1987, where he also trained in Pathology. He passed a postdoctoral research fellowship in Gynecological Pathology at the Johns Hopkins University, School of Medicine, in Baltimore, MD (USA) under mentorship of Profs. R.J. Kurman and Lora H. Ellenson. In 1999 he received his academic lecturership (docent) at the University of Graz and became a tenured faculty member.
His main focus of interest is molecular tumorigenesis of endometrial carcinoma. Other fields of interest are mesenchymal tumors of the uterus, epithelial ovarian neoplasm, cervical carcinoma and precursors and molecular and surgical pathology of breast carcinoma. He has published around 140 articles in peer reviewed journals, reviews and several book chapters.
He has been acting as tutor and lecturer in the German and Austrian divisions of the IAP, the European Society of Pathology and ESGO. He served as member of the WHO Committee for Classification of Tumours of the Female Genital Tract, (2002 and 2013) and is currently on the editorial board of Virchows Archiv as Associate Editor, the International Journal of Gynecological Pathology, Der Pathologe and Acta medicobiotechnica. Currently, he is President of the German IAP division, Past-President of the Austrian Society of Pathology/ Austrian IAP division and chair of the GYN and Breast Pathology Working Group of the German Society of Pathology.
Ignace Vergote, MD, PhD, is chair of the Leuven Cancer Institute and head of the Department of Obstetrics and Gynecology and Gynecologic Oncology at the Catholic University of Leuven, Belgium. He initially trained in obstetrics and gynecology at the University of Antwerp, Belgium, before specializing in gynecologic oncology in the Department of Gynecologic Oncology at the Norwegian Radium Hospital, where he later became a staff member and, in 1991, deputy chairman.
Professor Vergote is currently chair of the Belgian & Luxemburg Gynaecological Oncology Group (BGOG) and was the founder and first chairman of ENGOT (European Network of Gynaecologic Oncology Trial Groups), from 2007 until 2012. In 2013, he was chair of the Board of Medical Chairmen of the University Hospital Leuven. Since 2014, he has been a member of the board of directors of the University Hospital Leuven. He was chair of the EORTC-GCG from 1997 to 2003, and served as president of the European Society of Gynaecological Oncology (ESGO) for the period 2003-2005. For the period 2006-2008, he was the president of the International Gynecologic Cancer Society (IGCS). He was chair of the Flemish Society of Obstetrics and Gynaecology from 2008 to 2013.
In 2004, Professor Vergote received the Wertheim prize in Austria and the COBRA prize for surgical expertise in the Netherlands. In 2008, he became an honorary member of the Finnish Society of Gynaecology and Obstetrics. In 2012, he became an honorary member of the American College of Surgeons. Professor Vergote’s main areas of clinical and translational research focus on ovarian and uterine cancer. He has authored more than 800 original full papers in peer-reviewed journals, together with 50 book chapters, and he has edited several books on gynecologic oncology. He is editor of the European Journal of Cancer, and past-associate editor of Gynecologic Oncology and the International Journal of Gynaecological Cancer.
Philippe Morice is the head of the Department of Gynecologic Surgery in the Institut Gustave Roussy, Villejuif France and Full Professor at the University Paris-Sud. His main topics of clinical and translational research are: conservative management of gynecologic cancer, borderline ovarian tumors, cancer and pregnancy, radical surgery in advanced stage ovarian cancer, results and interest of lymphadenectomy in gynecological malignancies and interest of completion surgery after chemoradiation therapy in stage IB2/II cervical cancer.
Dominik Denschlag MD PhD FRCSC Dominik Denschlag graduated from the University of Mainz School of Medicine in 1998, and completed a residency in obstetrics and gynecology at the University of Freiburg, Germany in 2004. Aside from his clinical education he was able to work as a clinical scientist and was awarded a PhD in 1998. From 2004 to 2005 he completed a fellwoship in reproductive endocrinology and embryology at the University of Freiburg. Due to his main research interest in Fertility Preservation in Cancer Patients he went on to complete another fellwoship in gynencologic oncology from 2005 to 2007 at McGill University Montreal, Canada. Afterwards he went back to Germany and worked as senior consultant in obstetrics and gynecology at the University of Freiburg. In 2010 he was appointed as Associate Professor of obstetrics and gynecology at the University of Freiburg School of Medicine, Germany. In addition to his academic career Prof. Denschlag is heading the department of obstetrics and gynecology at the Hochtaunuskliniken Bad Homburg, Germany. Due to his broad expertise in Gynecologic Oncology as well as in REI in 2007 he became the chair of the ESGO Task Force for Fertility Preservation. Moreover he is a leading member of the AGO study group as well as an active member of the AGO Uterus committee. He has published over 50 articles in peer-reviewed journals.
Nicoletta Colombo, Italy
Prof. Nicoletta Colombo graduated in Medicine in 1980; she completed the Specialty in Obstetrics and Gynecology in 1984 from the University of Milan, Italy. After a training period at Charing Cross Hospital and Royal Marsden Hospital in London, she became clinical research associate at the Kaplan Cancer Center , New York University, where she worked from 1984 until 1986. Junior and later Senior Faculty at the Department of Obstetrics and Gynecology at the University of Milan from 1986 to 1994, in September 1994 she became Deputy Director and in July 2001 Director of the Gynecologic Oncology Unit, Division of Gynecology, European Institute of Oncology, Milan, Italy. Since October 1, 2002 she is Associate Professor of Obstetrics and Gynecology, University of Milan-Bicocca. Author of several publications in the field of gynecologic oncology, she is member of various professional societies such as the American Society of Clinical Oncology (ASCO), the Society of Gynecologic Oncologists (SGO) and the International Gynecological Cancer Society (IGCS), as well as Past President of the European Society of Gynecologic Oncology ( ESGO) and Senior Editor of the International Journal of Gynecological Cancer.
Heidi Fiegl, Austria
Adriaan Vanderstichele, BE
Ate Van der Zee, NL
Daniela Fischerova, Czech R.
In 2001, having completed her PhD study at the Leopold Franzens University in Innsbruck, Austria, she began to work as a postdoctoral research fellow at the Department of Gynaecology and Obstetrics.
In 2005 she moved to the University College London and in 2006 to the Tyrolean Cancer Research Institute in Innsbruck. During this time she intensively studied DNA methylation aberrations in women’s cancer. In 2007 she returned to the Department of Gynaecology and Obstetrics and there she established a research group focusing on the role of epigenetics and translational research in the field of breast and gynecological malignancies.
In 2008 she became a lecturer for experimental gynecology and since 2010 she is the head of the Laboratory for clinical biochemistry at this department. Most of her research concentrates on the identification of biomarkers to facilitate risk prediction and individualization of cancer treatment in female malignancies.
Adriaan Vanderstichele received his medical degree from the Catholic University Leuven in 2012. He started residency training in Obstetrics and Gynaecology at the University Hospitals Leuven and, in 2014, combined this with a research fellowship in gynaecological oncology under the guidance of professor Ignace Vergote.
The topic of his ongoing PhD project is the development and validation of cell-free DNA based assays in epithelial ovarian cancer, in close collaboration with the laboratory of Translational Genetics (prof. Diether Lambrechts) at the Vesalius Research Center of the Flemish Institute of Biotechnology (VIB). In this framework, he and professor Vergote initiated the CLIO study (Circulating tumor DNA guiding olaparib treatment in ovarian cancer), a prospective, randomized, multi-center academic trial where 160 relapsed ovarian cancer patients will be enrolled for PARP inhibitor monotherapy and monitoring with sequential cell-free DNA sampling.The study opened in October 2016.
Furthermore, Dr. Vanderstichele collaborates with the IOTA (International Ovarian Tumour Analysis) consortium in the ongoing prospective TRANS-IOTA trial, in order to integrate cell-free DNA testing in the presurgical assessment of adnexal masses. First results of this collaboration were published in Clinical Cancer Research in November 2016.
Dr. Vanderstichele has an interest in cancer genomics, bio-informatics and targeted therapies in ovarian cancer. He is a member of ESMO, OCAC, BGOG and ESGO.
Professor van der Zee is a Professor of Gynecologic Oncology, University Medical Center Groningen. Until December 2012, he was head of the Department of Gynecologic Oncology, University Medical Center Groningen, The Netherlands, which is one of the world leading centers with respect to clinical and translational research in Gynecologic Oncology.
Professor Van der Zee has recently initiated and established a managed clinical network for ovarian cancer for all hospitals in the North-East of the Netherlands (catchment area 3.5 million people), in which gynecologists and medical oncologists collaborate to improve the care for ovarian cancer patients and which forms a unique platform for translational research.
Prof. Van der Zee has also created a long and productive translational research line on prognostic and predictive factors in gynecologic cancer. He is leading a world-wide consortium (GROINSS-V-II), which performs landmark clinical studies in vulvar cancer. He co-authored > 250 peer-reviewed publications. Under his guidance 36 PhD theses were completed. Since January 2013, he joined the Board of Directors of the University Medical Center Groningen. He combines his management position with clinical research, performing surgery in Gynaecological Oncology, seeing patients during consulting hours, academic research and mentoring PhD students.
Professor Van der Zee is past President of the European Society for Gynecologic Oncology (2009-2011) and past president of the Dutch Working Party for Gynecologic Oncology. He serves and has served on various national and international advisory and program committees (eg. Dutch Cancer Society, NCRN UK, IGCS, ESGO, etc.). He is senior editor of the International Journal of Gynaecological Cancer.
Daniela Fischerova works as an associate professor of OBGYN at the First Medical Faculty of Charles University in Prague. She is fully specialized in obstetrics and gynecology, clinical oncology, and gynecological oncology and received her Ph.D. in experimental surgery.
Since 2016 she has been a board member of the International Society of Ultrasound in Obstetrics and Gynecology. She also serves as a vice president of the Czech Ultrasound Society in Obstetrics and Gynecology. Her main area of clinical research focus is the implementation of ultrasound in diagnosis, staging and in personalized management of gynecologic cancer.
She has received 7 awards for herpresentations at the World Congress of Ultrasound in Obstetrics and Gynecology and at the International Meeting of the European Society of Gynaecological Oncology. She is the author or co-author of more than 53 articles in journals with impact factor, and additionally more than 55 original full articles in her native language.
She has published 28 textbook chapters in international and Czech textbooks as well as one Czech-language textbook on Ultrasound in Gynecology and Obstetrics. She is also active in the field of postgraduate education in ultrasound imaging of gynecological cancer, she has produced educational DVDs distributed by ISUOG and ESGO and organises an International Workshop on Ultrasound in Gynecologic Oncology (IWUGO( in Prague. She serves as a tutor for gynecologic oncology ultrasound of international visitors at the Gynecologic Oncology Center (28 fellows since 2007).
Mansoor Raza Mirza, Denmark
Xavier Bosch, Spain
Cristiana Sessa, Switzerland
Sven Mahner, Germany
Chief Oncologist at the Rigshospitalet, Copenhagen University Hospital, Denmark and Medical Director of the NSGO (Nordic Society of Gynaecologic Oncology), Vice-Chairman of the DGCG (Danish Society of Gynaecologic Oncology), member of the board of directors of the GCIG (Gynecologic Cancer Inter Group) and Co-Chair of Phase 1-2 working group of the Gynecologic Cancer Inter Group (GCIG).
Mansoor R. Mirza is involved in the management of gynaecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education. He has broad experience in clinical protocol development, trial conduct and clinical trial regulations. He is author and principle investigator of several phase I, II and III studies.
He is sponsor on behalf of NSGO & DGCG of 6 clinical trials. He is chair/member of Independent Data Monitoring Committee (IDMC) of several international trials. He is senior author of national guidelines for the management of endometrial cancer, cervical cancer, vulvar cancer and non-epithelial ovarian cancer as well as of NSGO radiotherapy guidelines for cervical and vulvar cancers. He is co-author of ESMO-ESGO-ESTRO guidelines for endometrial cancer, ESGO guidelines for vulvar cancer and GCIG Ovarian cancer consensus guidelines. He is invited speaker at several international meetings, including keynote lectures and serves in multiple global advisory boards.
Dr. F. Xavier Bosch conducts epidemiological research focusing on cancers linked to infectious agents. His main research studies focus on cancer of the liver, the cervix, the skin, vagina, anus, penis and cancers of the head and neck. He has also conducted studies on diet and colorectal cancer and headed a program of implementation and methodological research in cancer registration.
Dr. Bosch’s research projects on viruses and cancer have been instrumental in demonstrating the causal role of Human Papilloma Virus (HPV) in cervical cancer and played a catalytic role for the initiation of the first vaccine trials and for the evaluation of HPV tests as screening tools. Dr. F. Xavier Bosch was an early introducer of the now called molecular epidemiology, by designing studies that integrate novel biological assays at DNA level to assess exposure to viral carcinogens. Relevant epidemiological field studies have been carried out in over 35 countries around the world, particularly in Latin America, Africa and Asia.
The final and more practical goal of his research has extended into the application of the aetiological knowledge to the prevention of cancer.
He served as Epidemiologist at the International Agency for Research on Cancer (Lyon, France 1982-1993) and was a Visiting Scientist at the National Cancer Institute (Washington, USA 2002).
He is the current Director of the Cancer Epidemiology Research Program at the Catalan Institute of Oncology (Institut Catala d’Oncologia, ICO) (Barcelona, Spain 1994-to date).
Dr. F.X. Bosch is also the Director of the IARC / Catalan Institute of Oncology Information Centre on HPV and Cancer.
Dr. F.X. Bosch has successfully interacted with international groups interested in epidemiological research and public health issues on virus and cancer. These include the World Health Organization (WHO), the International Agency for Research on Cancer (IARC), the Pan American Health Organization (PAHO), the Program for Appropriate Technology in Health (PATH), the European Research Organization on Genital Infection and Neoplasia (EUROGIN), the Asia Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN), the decision making research group at the Harvard University, the pathology group at the Cambridge University, among other. As a co-principal investigator and organizer of the HPV and Cancer Program at IARC, Dr. F.X. Bosch interacted with scientists in all continents, helped in the implementation of study protocols, assisted with technology transfer and encouraged human mobility efforts.
He is a meeting organizer of the International Papillomavirus Congress (HPV 2000) and member of the advisory board of the International Papillomavirus Society (IPV). EDUCATIONAL PROFILE: As part of the efforts to bridge knowledge with the medical and public health communities, Dr. Bosch initiated and heads since 2001 the international newsletter HPV Today, currently distributing more than 30,000 printed copies in five languages, and a regular electronic version of at least 40,000 subscriptions.
Dr. Bosch also heads the activities of the WHO/ICO Information Centre on HPV and Cancer, a systematic literature review initiative that generates relevant epidemiological and preventive information at country (190 countries) and regional levels.
Dr. F.X. Bosch’s genuine contributions to the cancer epidemiology field include a series of studies that i) demonstrated the causal association of the Human Papillomavirus (HPV) and invasive cervical cancer (Bosch et al. 1992, Muֳ±oz et al. 1992, Bosch et al. 2002), ii) established the co-factor role of the principal environmental exposures among HPV positive women (Moreno et al. 2002, Muֳ±oz et al. 2002, Plummer et al. 2003; Castellsague et al. 2002), and iii) set the scene for the identification of the international variation of HPV types and some of its major variants in cervical cancer (Bosch et al. 1995, Yamada et al. 1997, Walboomers et al. 1999, Muֳ±oz et al. 2004, de Sanjose et al 2010).
Dr. F.X. Bosch was active in the conduct of early studies investigating the role of HBV in liver cancer, and particularly was part of the research team for the Gambia Hepatitis Intervention Study (GHIS), a 40-year project designed to demonstrate the capacity of the HBV vaccines given soon after birth to prevent liver cancer amongst adults in a high risk population in Western Africa (Hall et al. 1987). Other contributions in the HBV and liver cancer field include the early assessment of the impact of the polymerase chain reaction (PCR) technology in quantifying the role of HBV and Hepatitis C Virus (HCV) in liver cirrhosis and liver cancer and some studies on dietary exposures to aflatoxin and liver cancer. As invited expert, Dr. F.X. Bosch conducted some major reviews on the role and safety levels of Aflatoxin in the food chain for the WHO / Federal Drug Administration Joint Expert Commission of Food Additives (JECFA) (Henry et al. 1999).
Dr. Bosch’s publications in relation to virus and cancer amount to over 500 original publications, over 25 monograph books and major reviews, and over 750 scientific communications at medical meetings.
Since 2009, Cristiana Sessa has been Professor at the University of Bern, Switzerland. Prof. Cristiana Sessa has been working at the Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona since 1981, she has been appointed as Head of Phase I-II Unit and Pharmacology and she is currently Vice Head of Medical Oncology and Head of Clinical Research.
She is the Bellinzona site Director of the Clinical Trial Unit of the Ente Ospedaliero Cantonale (CTU-EOC) since 2012. Cristiana Sessa is a Member of the European Society for Medical Oncology (ESMO), where she is a committee member of the ESMO Guidelines Working Group and of the Translational Research Working Group.
She is also President of the Swiss Group for Clinical Cancer Research (SAKK) New Anticancer Drugs project group and of the working group on Gynaecological tumors. Sheג€™s been appointed as Executive Board of the European Society of Gynecologic Oncology (ESGO) in 2013
Director of the Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Germany since 2015.
Associate Director Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2012-2015.
Senior Consultant Gynecologic Oncology at the University Medical, Center Hamburg-Eppendorf, Hamburg, Germany 2009-2012.
Ph.D. Thesis in Surgical and tumor-biological prognostic factors in ovarian cancer, University of Hamburg.
Over 100 publications in international peer-reviewed journals, 150+ published national and international congress contributions
Murat Gultekin, Turkey
Andreas du Bois, Germany
Ass. Prof. Dr. Murat Gultekin is the director of cancer control department of Turkish Ministry of Health, since 2012. He is a gynaecologic oncologist working in Hacettepe University Hospital in Ankara, the capital city of Turkey. He is organizing palliative care and cancer screening-preventive services to be distributed widely across the country. He has published numerous articles in cancer prevention, epidemiology and gynaecologic oncology, and he is the editor of three international textbooks, and also working in the editorial and reviewer boards of some international journals.
He is an executive board and scientific council member in European Society of Gynaecologic Oncology (ESGO), European Network of Young Gynaecologic Oncologists (ENYGO), European Network of Prevention in Gynaecological Oncology (ENPIGO), Middle East Cancer Consortium (MECC), Women Against Cervical Cancer (WACC), International Agency For Cancer Research (IARC), Blacksea Countries Coalition for Cervical and Breast Cancers and Asian Pacific Organization for Cancer Prevention (APOCP).
Andreas du Bois, MD, PhD Andreas du Bois, MD, PhD, is the director of the Department of Gynecology & Gynecologic Oncology at the Kliniken Essen Mitte(KEM) in Essen, Germany. Dr du Bois received his medical degree from the Albert Ludwigs University of Freiburg Faculty of Medicine in 1987, performed his residency and registered as a fellow in gynecology & obstetrics in 1993. He completed his habilitation and was awarded venia legendi in gynecology from the University of Freiburg in 1997.
Additionally, he was awarded venia legendi in gynecology from the University of Mainz in 2002. Prior to assuming his current appointment at the KEM in 2010, for 11 years Dr du Bois was the chair of the Department of Gynecology and Gynecologic Oncology at the Dr. Horst Schmidt Klinik (HSK) in Wiesbaden, Germany.
Dr du Bois is a member of many medical societies, including the European Society of Gynecologic Oncology (ESGO), the International Society of Gynecologic Cancer (ISGC), the American Society of Clinical Oncology (ASCO), and the German Cancer Society (DKG). He served as officer / council member in ESGO and Gynecologic Cancer Intergroup (GCIG) and was chair of the 3rd International Ovarian Cancer Consensus Conference (2004). He is founding member and is past-president of the European Network of Gynecologic Oncology Trial groups (ENGOT) and founding member and chairman of AGO Study Group (formerly AGO-OVAR). Dr du Bois authored more than 450 scientific articles, reviews, and book chapters.
He was awarded the Young Investigator Award (1995), the Arthur Walpole Prize (2006), the Ernst-Wertheim-Prizes (2006), the Quality of Life Research Award (2006), and the MDAnderson Madrid lifetime award (2016). In 2016 he was appointed Adjunct Professor University Vienna, Honorary Clinical Professor at the Centre for Experimental Cancer Medicine Queen Mary University of London, and was appointed Honorary Doctor (Dr. h.c.) of the Faculty of Medicine at Lund University in Sweden.
Denis Querleu, France
Patrice Mathevet, Switzerland
Nadeem R. Abu-Rustum, USA
Charlie Gourley, UK
Dr. Denis Querleu was appointed full professor and Chairman of the Department of Obstetrics and Gynecology in 2011, then adjunct professor in 2013. Prior to joining McGill, Dr. Querleu was full professor in Obstetrics and Gynecology at the University of Lille, France, then in Oncology at the Université Paul Sabatier in Toulouse, France , where he was elevated to “Classe Exceptionnelle” the highest academic ranking in French universities. At the same time, he was head of the Surgery Department and of the Gynecologic Oncology Division, as well as Deputy Director of International Affairs, at the Toulouse Cancer Center . He was also head of Surgery at the Claudius Regaud Cancer Center. A dedicated researcher, Dr. Querleu served as the Chairman of the Experimental Research Department at the Université de Lille, France, for eight years. He has also served as President of the Société française de chirurgie pelvienne and of the Société française d’oncologie gynécologique. He is currently Council member of the ESGO, and chair of the Guidelines Committee. His clinical activities are currently based at the Institut Bergonié, Comprehensive Cancer Center in Bordeaux, France.
A pioneer in advanced laparoscopic surgery for gynecological cancer, Dr. Querleu has been involved in teaching and training fellows and attending staff in 26 countries around the world, as well as collaborating in training members of leading institutions such as the Mayo Clinic and Memorial Sloan-Kettering Cancer Center . Additionally, he has worked with France’s Institut National du Cancer to establish nationwide recommendations for clinical practice and to organize cancer care; published over 300 papers and written or contributed to textbooks and chapters in books; served as an editorial board member or a reviewer of numerous medical journals, and organized meetings of international societies.
Mathevet Patrice is the Head of department of gynecology at Centre Hospitalo-Universitaire Vaudois (CHUV) in Lausanne, Switzerland.
Patrice Mathevet, received an MD degree in Gynecology-Obstetrics and a PhD in Genetics and Immunology from Lyon university in 1990 and 2002, respectively. He worked in Lyon in the Department of Gynecologic Oncology, E. Herriot Hospital. From 2005 to 2012, he was on the faculty of the Department of Gynecologic Oncology, E. Herriot Hospital, in charge of the Breast Clinic.In 2013 he has been appointed Head of the Department of Gynecology of the Centre Hospitalo-Universitaire Vaudois (CHUV), University Hospital. He spent several months in 1993 and 1998 at the MD Anderson Cancer Center (Houston, Tx, USA) as visiting Assistant Professor.
Prof. Mathevet’s research is being directed towards the following topics:
>Surgical treatment of cervical carcinoma: vaginal radical trachelectomy, sentinel node technique
> Biology of cervical carcinoma: lymphatic dissemination, lymphangiogenesis, therapeutic vaccine
> Laparoscopic surgery: laparoscopic para-aortic lymph-node dissection, laparoscopic radical hysterectom
Nadeem R. Abu-Rustum, M.D. is the Chief of the Gynecology Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center in New York. He is the AVON Chair for Gynecologic Oncology and a Professor at Weill Cornell Medical College in New York and is the Vice-Chair for Technology Development at Memorial Sloan Kettering Cancer Center.
He has authored or co-authored more than 200 publications and is co-author to numerous book chapters and three textbooks in gynecologic oncology. He is in full-time practice of gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York.
Charlie Gourley graduated in Genetics and Medicine from Glasgow University in 1991 and 1994 respectively. From 1998 to 2005 he trained in Medical Oncology at the Edinburgh Cancer Centre, during which time he obtained a PhD in ovarian cancer genetics and received an NHS Education for Scotland Clinician Scientist Award. He was appointed Senior Lecturer in Medical Oncology at the University of Edinburgh Cancer Research Centre in 2005, Reader in Medical Oncology in 2011 and Professor of Medical Oncology (Personal Chair) in 2012. He received a Scottish Senior Clinical Fellowship Award in 2010.
Professor Gourley’s research focuses on trials of novel targeted agents in gynaecological cancer and the use of translational readouts from these studies in order to facilitate individualisation of care. He has led research demonstrating the propensity for ovarian cancer arising in BRCA1/2 germline mutation carriers to metastasise to liver, lungs and spleen and has used gene expression data to identify subgroups of high grade serous ovarian cancer that have significantly different prognosis and which are characterised by angiogenic and immune processes.
Current priorities of his laboratory group include: further investigation of drug resistance characteristics of BRCA1/2 and HNPCC-deficient ovarian cancer; validation of the existence of a pro-angiogenic subgroup of ovarian cancer using clinical material from a randomised trial of antiangiogenic therapy in ovarian cancer; analysis of pathways which characterise ovarian cancer subgroups in order to inform future trials of personalised therapy.
Clinical trials priorities include: leading an international randomised phase III trial of a MEK inhibitor in relapsed or persistent low grade serous ovarian cancer; leading further PARP inhibitor studies within genetically defined patient populations; further investigating and utilising the optimal intraperitoneal drug regime in an effort to maximise patient survival. Professor Gourley’s research currently receives funding from the European Union (FP7), Cancer Research UK, the Scottish Chief Scientist’s Office, the Scottish Funding Council, Ovarian Cancer Action and the Nicola Murray Foundation.
Michael Halaska, Czech R.
Rene Laky, Austria
Charles Redman, UK
Medical director of the department of Obstetrics and Gynecology, 3rd Medical Faculty, Charles University in Prague, Faculty Hospital Kralovske Vinohrady and member of the Grant agency of the Charles University in Prague since 2010.
President elect of ENYGO (2013-2015), and member of the executive committee of ENYGO during 2011-2015 as well as the organizer of the International Conference INCIP in 2017, and the 2nd ESGO/ENYGO Masterclass in Gynaecological Oncology.
Main author or coauthor of 46 impact factor publications, 48 peer-reviewed publications, and main author of 70 lectures.
Rene Laky, MD, Division of Gynecology Medical University Graz, Austria.
He is the current President of ENYGO.
Consultant Gynaecologist and Lead Colposcopist at the University Hospitals of the North Midlands. Was CRC Research Fellow in Gynaecological Oncology at Birmingham University. Was Chair of the BSCCP Training and Certification committee when the BSCCP/RCOG Diploma and Certification was introduced.
Is currently President of the European Federation for Colposcopy.